Trials / Recruiting
RecruitingNCT06660147
Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer
PAOLA-1 Ancillary Study: Retrospective Validation of KELIM as a Predictive and Prognostic Factor for Maintenance Treatment With PARP Inhibitor After Platinum-Based Chemotherapy in First-Line Ovarian Cancer
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 327 (estimated)
- Sponsor
- ARCAGY/ GINECO GROUP · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to understand whether it is possible to predict the effectiveness of maintenance treatment with PARP inhibitors following first-line chemotherapy in ovarian cancer, and thus better target the patients who benefit from this treatment
Conditions
Timeline
- Start date
- 2023-12-11
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
- First posted
- 2024-10-28
- Last updated
- 2024-10-28
Locations
24 sites across 2 countries: France, Monaco
Source: ClinicalTrials.gov record NCT06660147. Inclusion in this directory is not an endorsement.